ZA963907B - Insolated nucleic acid molecules peptides which form complexes with mhc molecule hla-a2 and uses thereof - Google Patents

Insolated nucleic acid molecules peptides which form complexes with mhc molecule hla-a2 and uses thereof

Info

Publication number
ZA963907B
ZA963907B ZA963907A ZA963907A ZA963907B ZA 963907 B ZA963907 B ZA 963907B ZA 963907 A ZA963907 A ZA 963907A ZA 963907 A ZA963907 A ZA 963907A ZA 963907 B ZA963907 B ZA 963907B
Authority
ZA
South Africa
Prior art keywords
nucleic acid
acid molecules
mhc molecule
form complexes
molecule hla
Prior art date
Application number
ZA963907A
Other languages
English (en)
Inventor
Yannick Guilloux
Franchine Jotereau
Thierry Boon-Falleur
Sophie Lucas
Vincent Brichard
Original Assignee
Ludwig Inst Cancer Res
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Inst Nat Sante Rech Med filed Critical Ludwig Inst Cancer Res
Publication of ZA963907B publication Critical patent/ZA963907B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA963907A 1995-06-07 1996-05-16 Insolated nucleic acid molecules peptides which form complexes with mhc molecule hla-a2 and uses thereof ZA963907B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/487,135 US5821122A (en) 1995-06-07 1995-06-07 Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof

Publications (1)

Publication Number Publication Date
ZA963907B true ZA963907B (en) 1997-03-11

Family

ID=23934549

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA963907A ZA963907B (en) 1995-06-07 1996-05-16 Insolated nucleic acid molecules peptides which form complexes with mhc molecule hla-a2 and uses thereof

Country Status (12)

Country Link
US (3) US5821122A (de)
EP (1) EP0845032B1 (de)
JP (1) JP3849102B2 (de)
AT (1) ATE209680T1 (de)
AU (1) AU704934B2 (de)
CA (1) CA2223694C (de)
DE (1) DE69617440T2 (de)
DK (1) DK0845032T3 (de)
ES (1) ES2167561T3 (de)
PT (1) PT845032E (de)
WO (1) WO1996040039A2 (de)
ZA (1) ZA963907B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032855A1 (en) 1997-01-27 1998-07-30 Ludwig Institute For Cancer Research Lage-1 tumor associated nucleic acids
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
EP1266221A1 (de) * 2000-01-20 2002-12-18 Ludwig Institute For Cancer Research An hla-b35 und hla-b44 bindende mage antigene peptide
ES2331348T3 (es) 2000-09-15 2009-12-30 Pasteur Institut Vectores proteinicos para el suministro de moleculas a las celulas que expresan cd11b.
CA2433877C (en) 2001-01-17 2014-11-18 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US6607151B2 (en) * 2001-08-16 2003-08-19 Morris Samelson Ultra fine dead sea mineral compound and method of manufacture
EP1467759A4 (de) 2002-01-30 2006-05-31 Brigham & Womens Hospital Zusammensetzungen und verfahren im zusammenhang mit tim-3, a th1-spezifischem zelloberflächenmolekül
ES2337694T3 (es) * 2003-11-21 2010-04-28 Institut Pasteur Toxina de adenilato ciclasa recombinante de bordetella que induce las respuestas de la celula t contra los antigenos tumorales.
US20070026022A1 (en) * 2004-11-19 2007-02-01 Gilles Dadaglio Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
AU2005265182B2 (en) * 2004-06-17 2012-06-21 Mannkind Corporation Epitope analogs
AU2005326758B2 (en) * 2004-06-23 2011-07-14 Board Of Regents Of The University Of Texas System Methods and compositions for the detection of biological molecules using a two particle complex
US8481297B2 (en) 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
US20120171246A1 (en) 2009-09-10 2012-07-05 Yale University Immunization to reduce neurotoxicity during treatment with cytolytic viruses
WO2011056993A1 (en) 2009-11-04 2011-05-12 Yale University Compositions and methods for treating cancer with attenuated oncolytic viruses
CA2876209A1 (en) 2012-06-15 2013-12-19 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
SG11201506991VA (en) 2013-03-15 2015-10-29 Adaptive Biotechnologies Corp Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
US10874621B2 (en) 2013-10-17 2020-12-29 The Brigham And Women's Hospital, Inc. Cationic nanoparticles for co-delivery of nucleic acids and therapeutic agents
EP3721875B1 (de) 2014-05-09 2023-11-08 Yale University Mit hyperverzweigtem polyglycerol beschichtete partikel und verfahren zu deren herstellung
US20180126014A1 (en) 2015-04-15 2018-05-10 Yale University Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
WO2017095751A1 (en) 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
US20190117799A1 (en) 2016-04-01 2019-04-25 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
WO2018053434A1 (en) 2016-09-16 2018-03-22 The Johns Hopkins University Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery
US20200085758A1 (en) 2016-12-16 2020-03-19 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
WO2018196782A1 (en) 2017-04-27 2018-11-01 The University Of Hong Kong Use of hcn inhibitors for treatment of cancer
US11478433B2 (en) 2017-06-23 2022-10-25 Yale University Nanomaterials with enhanced drug delivery efficiency
EP4377338A2 (de) 2021-07-27 2024-06-05 Novab, Inc. Manipulierte vlrb-antikörper mit immuneffektorfunktionen
US20230172870A1 (en) 2021-12-08 2023-06-08 Yale University Surface conjugation to poly(amine-co-ester) nanoparticles for targeting to cells and tissues
WO2023147552A1 (en) 2022-01-28 2023-08-03 University Of Georgia Research Foundation, Inc. Radiosensitizing compositions and methods of use thereof
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024112867A1 (en) 2022-11-23 2024-05-30 University Of Georgia Research Foundation, Inc. Compositions and methods of use thereof for increasing immune responses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
AU679965B2 (en) * 1992-12-22 1997-07-17 Ludwig Institute For Cancer Research Methods for detection and treatment of individuals having abnormal cells expressing HLA-A2/tyrosinase peptide antigens
US5856091A (en) * 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5997870A (en) * 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules

Also Published As

Publication number Publication date
EP0845032A4 (de) 2000-05-10
EP0845032A2 (de) 1998-06-03
AU704934B2 (en) 1999-05-06
ES2167561T3 (es) 2002-05-16
JP2001520506A (ja) 2001-10-30
DE69617440D1 (de) 2002-01-10
US5886145A (en) 1999-03-23
DE69617440T2 (de) 2002-08-08
AU5676996A (en) 1996-12-30
JP3849102B2 (ja) 2006-11-22
DK0845032T3 (da) 2002-05-06
EP0845032B1 (de) 2001-11-28
CA2223694A1 (en) 1996-12-19
CA2223694C (en) 2003-06-24
ATE209680T1 (de) 2001-12-15
PT845032E (pt) 2002-05-31
WO1996040039A2 (en) 1996-12-19
WO1996040039A3 (en) 2000-03-23
US5821122A (en) 1998-10-13
US5958711A (en) 1999-09-28

Similar Documents

Publication Publication Date Title
ZA963907B (en) Insolated nucleic acid molecules peptides which form complexes with mhc molecule hla-a2 and uses thereof
ZA944196B (en) Isolated peptides which form complexes with MHC molecule HLA-C-clone 10 and uses thereof
ZA958039B (en) Isolated nucleic acid molecule coding for tumor rejection antigen precursor dage and uses thereof
ATE345387T1 (de) Verbindungen und verfahren für therapie und diagnose von lungenkrebs
ZA941644B (en) Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
FI960268A0 (fi) Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä
EA200101037A1 (ru) Соединения и способы для лечения и диагностики рака легкого
NZ302821A (en) isolated truncated nucleic acid molecules which code for GAGE tumour rejection antigen precursors
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
EP0979235A4 (de) Isoliertes nukleinsäuremolekül, das die tumorabstossungs-antigenvorläufer mage- c1 und mage-c2 kodiert und seine verwendung
CA2213001A1 (en) Isolated nucleic acid molecule encoding peptides which form complexes with mhc molecule hla-cw*1601 and uses thereof
CA2165435A1 (en) Isolated peptides which form complexes with mhc molecule hla-c-clone 10 and uses thereof
TW372973B (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof